ZIOPHARM to Present at the Jefferies Gene Editing/Therapy Summit
October 05 2016 - 07:00AM
ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that Laurence
Cooper, M.D., Ph.D., Chief Executive Officer, will present at the
Jefferies Gene Editing/Therapy Summit on Tuesday, October 11, 2016
at 2:40 p.m. ET in New York City.
About ZIOPHARM Oncology,
Inc.:
ZIOPHARM Oncology is a Boston,
Massachusetts-based biotechnology company employing novel gene
expression, control and cell technologies to deliver safe,
effective and scalable cell- and viral-based therapies for the
treatment of cancer and graft-versus-host-disease. The Company's
immuno-oncology programs, in collaboration with Intrexon
Corporation (NYSE:XON) and the MD Anderson Cancer Center, include
chimeric antigen receptor T cell (CAR-T) and other adoptive
cell-based approaches that use non-viral gene transfer methods for
broad scalability. The Company is advancing programs in multiple
stages of development together with Intrexon Corporation's
RheoSwitch Therapeutic System® technology, a switch to turn on and
off, and precisely modulate, gene expression in order to improve
therapeutic index. The Company's pipeline includes a number of
cell-based therapeutics in both clinical and preclinical testing
which are focused on hematologic and solid tumor malignancies.
Contact:
Lori Ann Occhiogrosso
ZIOPHARM Oncology, Inc.
617-259-1987
locchiogrosso@ziopharm.com
David Pitts
Argot Partners
212-600-1902
david@argotpartners.com
ZIOPHARM Oncology (NASDAQ:ZIOP)
Historical Stock Chart
From Feb 2024 to Mar 2024
ZIOPHARM Oncology (NASDAQ:ZIOP)
Historical Stock Chart
From Mar 2023 to Mar 2024